A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia

被引:0
作者
Lin, Dee [1 ]
Pilon, Dominic [2 ]
Morrison, Laura [2 ]
Shah, Aditi [2 ]
Lafeuille, Marie-Helene [2 ]
Lefebvre, Patrick [2 ]
Benson, Carmela [1 ]
机构
[1] Janssen Sci Affairs LLC, Titusville, NJ USA
[2] Anal Grp Inc, 1190 Ave Canadiens Demontreal, Tour Deloitte, Suit, Montreal, PQ H3B 0G7, Canada
关键词
CARE RESOURCE UTILIZATION; TREATMENT PATTERNS; UNITED-STATES; IMPACT; UNDERINSURANCE; MEDICATIONS; PREVALENCE; ADHERENCE; DRUGS;
D O I
10.1007/s40801-023-00376-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Patient affordability is an important nonclinical consideration for treatment access among patients with schizophrenia. Objective This study evaluated and measured out-of-pocket (OOP) costs for antipsychotics (APs) among Medicaid beneficiaries with schizophrenia. Methods Adults with a schizophrenia diagnosis, >= 1 AP claim, and continuous Medicaid eligibility were identified in the -MarketScan (R) Medicaid Database (1 January 2018-31 December 2018). OOP AP pharmacy costs ($US 2019) were normalized for a 30-day supply. Results were descriptively reported by route of administration [ROA; orals (OAPs), long-acting injectables (LAIs)], generic/branded status within ROAs, and dosing schedule within LAIs. The proportion of total (pharmacy and medical) OOP costs AP-attributable was described. Results In 2018, 48,656 Medicaid beneficiaries with schizophrenia were identified (mean age 46.7 years, 41.1% female, 43.4% Black). Mean annual total OOP costs were $59.97, $6.65 of which was AP attributable. Overall, 39.2%, 38.3%, and 42.3% of beneficiaries with a corresponding claim had OOP costs > $0 for any AP, OAP, and LAI, respectively. Mean OOP costs per patient per 30-day claim (PPPC) were $0.64 for OAPs and $0.86 for LAIs. By LAI dosing schedule, mean OOP costs PPPC were $0.95, $0.90, $0.57, and $0.39 for twice-monthly, monthly, once-every-2-months, and once-every-3-months LAIs, respectively. Across ROAs and generic/branded status, projected OOP AP costs per-patient-per-year for beneficiaries assumed fully adherent ranged from $4.52 to $13.70, representing < 25% of total OOP costs. Conclusion OOP AP costs for Medicaid beneficiaries represented a small fraction of total OOP costs. LAIs with longer dosing schedules had numerically lower mean OOP costs, which were lowest for once-every-3-months LAIs among all APs.
引用
收藏
页码:471 / 480
页数:10
相关论文
共 37 条
[21]   Prevalence and Predictors of Underinsurance Among Low-Income Adults [J].
Magge, Hema ;
Cabral, Howard J. ;
Kazis, Lewis E. ;
Sommers, Benjamin D. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 (09) :1136-1142
[22]  
National Alliance on Mental Illness, 2021, MENT HLTH NUMB ARL V
[23]  
National Committee for Quality Assurance, 2023, HEDIS Measures and Technical Resources. Follow-up After Emergencey Department Visit for Alcohol and Other Drug Abuse or Dependence
[24]  
National Conference of State Legislatures, MED PRESCR DRUG LAWS
[25]  
National Institute for Health and Care Excellence, PSYCH SCHIZ AD PREV
[26]   National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States [J].
Patel, Charmi ;
Pilon, Dominic ;
Gupta, Deepshekhar ;
Morrison, Laura ;
Lafeuille, Marie-Helene ;
Lefebvre, Patrick ;
Benson, Carmela .
JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) :792-807
[27]   Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study [J].
Patel, Charmi ;
Emond, Bruno ;
Morrison, Laura ;
Lafeuille, Marie-Helene ;
Lefebvre, Patrick ;
Lin, Dee ;
Kim, Edward ;
Joshi, Kruti .
CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) :665-674
[28]   Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries [J].
Pilon, Dominic ;
Patel, Charmi ;
Lafeuille, Marie-Helene ;
Zhdanava, Maryia ;
Lin, Dee ;
Cote-Sergent, Aurelie ;
Rossi, Carmine ;
Joshi, Kruti ;
Lefebvre, Patrick .
CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (10) :1811-1819
[29]   Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics [J].
Pilon, Dominic ;
Tandon, Neeta ;
Lafeuille, Marie-Helene ;
Kamstra, Rhiannon ;
Emond, Bruno ;
Lefebvre, Patrick ;
Joshi, Kruti .
CLINICAL THERAPEUTICS, 2017, 39 (10) :1972-1985
[30]   Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic [J].
Pilon, Dominic ;
Joshi, Kruti ;
Tandon, Neeta ;
Lafeuille, Marie-Helene ;
Kamstra, Rhiannon L. ;
Emond, Bruno ;
Lefebvre, Patrick .
PATIENT PREFERENCE AND ADHERENCE, 2017, 11 :619-629